CalciMedica Inc. (NASDAQ:CALC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of CalciMedica Inc. (NASDAQ:CALC) have been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $50.00.

A number of research firms have recently issued reports on CALC. Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. UBS Group restated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Guggenheim initiated coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 49,794 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average cost of $4.00 per share, with a total value of $199,176.00. Following the completion of the acquisition, the director directly owned 212,654 shares of the company’s stock, valued at $850,616. This represents a 30.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. 180 Wealth Advisors LLC grew its stake in CalciMedica Inc. (NASDAQ:CALC) by 297.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 126,500 shares of the company’s stock after acquiring an additional 94,650 shares during the period. 180 Wealth Advisors LLC owned 0.80% of CalciMedica worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

CalciMedica Stock Performance

Shares of CalciMedica stock opened at $1.92 on Monday. CalciMedica has a 12-month low of $1.87 and a 12-month high of $36.00. The stock has a market capitalization of $13.11 million, a P/E ratio of -0.28 and a beta of 0.83. The company has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $3.41. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. Research analysts expect that CalciMedica will post -5.25 earnings per share for the current fiscal year.

About CalciMedica

CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research is centered on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead investigational product is Auxora, also known as zelnecirnon or CM4620. The selective CRAC channel inhibitor has been evaluated in clinical studies for conditions including acute pancreatitis and associated acute kidney injury, as well as other diseases involving excessive inflammation.